27
Pharma & HealthcareAvoid
Quant Healthcare
Quant · Direct–Growth · rank #16 of 19 by Smart Score
Data updated
Trailing returns
1 Year
12.0%
+16.7% vs index
3 Years
18.9%
+9.5% vs index
5 Years
—
Since launch
20.1%
Year-by-year performance
2024
+31.9%+16.2% vs index
2025
-3.6%-11.3% vs index
2026
+16.5%+22.5% vs index
Why this score
Quant Healthcare scores 27/100 — #16 of 19 Pharma & Healthcare fund (Avoid). The main drag is its volatility (better than only 3% of peers).
Each bar shows the fund's percentile vs Pharma & Healthcare peers — a longer bar beats more of the category.
Volatility18.38 · 3rd percentile in category
3Y return18.86% · 29th percentile in category
Expense ratio1.51% · 5th percentile in category
Sortino ratio0.98 · 23rd percentile in category
Fund size431.49 Cr · 29th percentile in category
Sharpe ratio0.83 · 41st percentile in category
Top holdings
1.Glaxosmithkline Pharmaceuticals Ltd9.69%
2.Divi's Laboratories Ltd.9.63%
3.Zydus Lifesciences Ltd9.39%
4.Glenmark Pharmaceuticals Limited9.34%
5.Strides Pharma Science Ltd9.04%
17 disclosed equity positions · portfolio as of Sept 2026 · weights are % of total corpus.